Trademark Overview
On Wednesday, December 13, 2023, a trademark application was filed for SNAPAAV with the United States Patent and Trademark Office. The USPTO has given the SNAPAAV trademark a serial number of 98313180. The federal status of this trademark filing is APPROVED FOR PUBLICATION as of Thursday, September 19, 2024. This trademark is owned by National Resilience, Inc.. The SNAPAAV trademark is filed in the Treatment & Processing of Materials Services and Computer & Software Services & Scientific Services categories with the following description:
Custom manufacturing of pharmaceuticals, biological preparations, chemical preparations, and reagents for others; biomanufacturing for others, namely, manufacturing of gene therapies, cell therapies, viral vectors, vaccines, oligonucleotides, and proteins using biological organisms in the manufacturing process; biomanufacturing for others, namely, platforms for manufacturing of gene therapies, cell therapies, viral vectors, vaccines, oligonucleotides, and proteins using biological organisms in the manufacturing process; consulting services in the field of manufacturing processes for pharmaceuticals, biological preparations, chemical preparations, gene therapies, cell therapies, viral vectors, vaccines, oligonucleotides, and proteins; custom processing and manufacture of vectors, cells and proteins for use in the field of biotechnology
Research, development, and consulting services related thereto in the field of manufacturing processes for pharmaceuticals, biological preparations, chemical preparations, gene therapies, cell therapies, viral vectors, vaccines, oligonucleotides, and proteins; genetic engineering services, namely, research in the field of genetics; biotechnology research and development; scientific, pharmaceutical, and medical research services in the field of biological treatment and bioproduction; design and development of biotechnology platforms relating to biological treatment for use in the manufacture of pharmaceuticals, biological preparations, chemical preparations, gene therapies, cell therapies, viral vectors, vaccines, oligonucleotides, and proteins; providing scientific research information, namely, provision of information for research and development of biopharmaceuticals that are manufactured using biological treatment and bioproduction platforms; development of new technology for others...
